Abstract
Dysregulation of sirtuin 6 (SIRT6) is actively involved in tumor progression. High levels of SIRT6 have been associated with hepatocellular carcinoma and non‐small cell lung cancer, and SIRT6 facilitates growth and metastasis of cancer cells. However, the clinical significance and biological function of SIRT6 are not known for osteosarcoma (OS). Here, we report that SIRT6 was notably overexpressed in OS tissues compared with non‐cancerous specimens. The high level of SIRT6 was prominently correlated with malignant clinical parameters and poor prognosis of OS patients. SIRT6 was also up‐regulated in OS cells. SIRT6 knockdown inhibited the invasion and migration of Saos‐2 and U2OS cells in vitro, while SIRT6 restoration increased these cellular biological behaviors in MG‐63 cells. Mechanistically, SIRT6 up‐regulated expression of matrix metallopeptidase 9 (MMP9) in OS cells. MMP9 restoration partially abolished the effects of SIRT6 knockdown on OS cells, with increased cell migration and invasion. MMP9 knockdown reduced migration and invasion of SIRT6‐overexpressing MG‐63 cells. Furthermore, SIRT6 positively modulated the levels of phosphorylated extracellular signal‐regulated kinases 1 and 2 (ERK1/2). PD098059 and PD0325901, inhibitors of mitogen‐activated protein kinase kinase (MEK), blocked the regulatory effects of SIRT6 on p‐ERK1/2 and MMP9 levels, suggesting that SIRT6 regulated MMP9 abundance probably through the MEK–ERK1/2 pathway. These results suggest that SIRT6 may act as a prognostic predictor and a drug target for OS patients.
Highlights
Dysregulation of sirtuin 6 (SIRT6) is actively involved in tumor progression
Our data disclosed that the levels of SIRT6 protein in OS tissues were increased compared with normal bone (NB) specimens (P < 0.05, Fig. 1A)
As previous studies have identified that the mitogenactivated protein kinase kinase (MEK)–extracellular signal-regulated kinases 1 and 2 (ERK1/2) pathway regulates matrix metallopeptidase 9 (MMP9) expression and subsequently controls cancer cell migration and invasion [21,26], we investigated whether the mitogen-activated protein kinase kinase (MEK)–ERK1/2 pathway was involved in the role of SIRT6 in OS
Summary
Dysregulation of sirtuin 6 (SIRT6) is actively involved in tumor progression. High levels of SIRT6 have been associated with hepatocellular carcinoma and non-small cell lung cancer, and SIRT6 facilitates growth and metastasis of cancer cells. The high level of SIRT6 was prominently correlated with malignant clinical parameters and poor prognosis of OS patients. SIRT6 restrains proliferation via induction of apoptosis by repressing survivin in endometrial cancer [8] It is a key regulator of metabolism [5] and has been reported to down-regulate gluconeogenesis in hepatocytes by Abbreviations ERK1/2, extracellular signal-regulated kinases 1 and 2; HCC, hepatocellular carcinoma; MEK, mitogen-activated protein kinase kinase; MMP9, matrix metallopeptidase 9; NSCLC, non-small cell lung cancer; OS, osteosarcoma; SIRT6, sirtuin 6. SIRT6 is reported to be overexpressed in HCC and its high expression is associated with malignant clinical features and shorter survival [14,15]. In non-small cell lung cancer (NSCLC), SIRT6 overexpression correlates with a poor prognosis and contributes to metastasis and chemotherapy resistance [21,22]. The clinical significance and biological role of SIRT6 in OS remain largely unknown
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
